On 11 JUNE Amarin Corporation plc (ADR) (NASDAQ:AMRN) announced the publication of a retrospective analysis of patient cases that examined the effect on lipid parameters in hyperlipidemic patients who were switched from Lovaza®(omega-3-acid ethyl esters) capsules, a mixture of omega fatty acids, to Vascepa®(icosapent ethyl) capsules, the only pure-EPA prescription omega-3 product, to potentially achieve better outcomes in triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) levels.1 During the studied period, most of the 14 patients switched to Vascepa experienced reductions in levels of triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and non-high-density lipoprotein cholesterol (non-HDL-C). Amarin Corporation plc (ADR) (NASDAQ:AMRN) weekly performance is 3.90%. On last trading day company shares ended up $1.60. Analysts mean target price for the company is $2.22. Amarin Corporation plc (ADR) (NASDAQ:AMRN) distance from 50-day simple moving average (SMA50) is 4.95%.
On 20 JUNE CARDIOME PHARMA CORP (NASDAQ:CRME) reported ($0.20) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.11) by $0.09. The company had revenue of $7.60 million for the quarter, compared to the consensus estimate of $8.08 million. On average, analysts predict that Cardiome Pharma will post $-0.55 earnings per share for the current fiscal year. CARDIOME PHARMA CORP (NASDAQ:CRME) shares advanced 7.31% in last trading session and ended the day on $8.07. CRME Gross Margin is 80.00% and its return on assets is -45.20%. CARDIOME PHARMA CORP (NASDAQ:CRME) quarterly performance is -8.09%.
On 17 JUNE ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) announced it has earned a $10 million milestone payment from Biogen Idec associated with the validation of an undisclosed target to treat a neurological disorder. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) shares moved up 5.28% in last trading session and was closed at $36.66, while trading in range of $34.59 – $36.80. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) year to date (YTD) performance is -7.98%.
On 9 JUNE DURECT Corporation (NASDAQ:DRRX) announced that Matt Hogan, Chief Financial Officer, will be presenting at The 25th Annual Wall Street Analyst Forum Institutional Investor Conference. The conference is being held at the University Club located at 1 West 55th Street in New York City. DURECT Corporation (NASDAQ:DRRX) ended the last trading day at $1.62. Company weekly volatility is calculated as 4.36% and price to cash ratio as 10.06. DURECT Corporation (NASDAQ:DRRX) showed a positive weekly performance of 6.58%.